Atlas Trials

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer

Clinical trial NCT03901339 · COMPLETED

Trial details

NCT number
NCT03901339
Sponsor
Gilead Sciences
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Metastatic Breast Cancer
Start date
2019-05-08
Primary completion
2023-10-20
Enrollment
543

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.